Sarcomas

The FDA has placed a partial clinical hold on a planned pivotal trial examining an investigational T-cell therapy in patients with myxoid round cell liposarcoma.

Andrew S. Brohl, MD, discusses some of the recent findings of genomic studies of sarcomas.

Researchers are focusing genomic sequencing studies on many different types of sarcomas to emphasize the significant heterogeneity and the unique molecular mechanisms underlying the development of these cancers.

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the use of nanotechnology as a treatment for patients with sarcomas.

Treatment with aldoxorubicin failed to improve progression-free survival compared with investigator's choice of therapy for patients with advanced soft tissue sarcoma.

Noah Federman, MD, discusses challenges with treating pediatric patients and adolescent and young adults with sarcomas and ongoing efforts to overcome these obstacles.

Brian A. Van Tine, MD, PhD, discusses ongoing research in sarcomas, as well as provides insight on the impact existing drugs are making on the treatment landscape and what community oncologists need to know about this ever-changing field.

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses treatment challenges for patients with soft tissue sarcoma.

Jonathan C. Trent, MD, PhD, discusses notable findings in sarcomas that emerged at the 2016 ASCO Annual Meeting, as well as what lies ahead for the field of sarcomas.

George D. Demetri, MD, discusses current trends in sarcoma care, how the field of sarcoma has paved the way for other tumor types, and emerging therapeutic advances in the field.

The European Commission has approved eribulin mesylate (Halaven) as a treatment for patients with advanced or unresectable liposarcoma following anthracycline-based chemotherapy.

Junji Matsui, PhD, senior director, Eisai, discusses a preclinical study of eribulin (Halaven) demonstrating anti-proliferative activity in select soft tissue sarcoma cell lines.

The FDA has granted the PDGFRα antagonist olaratumab a priority review for use in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma who are not good candidates for radiotherapy or surgery.

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the evolving and advancing field of sarcoma.